Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
Identifieur interne : 004665 ( Main/Exploration ); précédent : 004664; suivant : 004666Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
Auteurs : RBID : pubmed:7591213English descriptors
- KwdEn :
- Antibodies, Anti-Idiotypic (metabolism), Antibodies, Bispecific (metabolism), Cells, Cultured, Endocytosis, Haptens (metabolism), Humans, Hydrogen-Ion Concentration, Immunoglobulin M (immunology), Indium Radioisotopes (diagnostic use), Iodine Radioisotopes (diagnostic use), Lymphoma, B-Cell (metabolism), Receptors, Antigen, B-Cell (immunology), Receptors, Antigen, B-Cell (metabolism).
- MESH :
- chemical , diagnostic use : Indium Radioisotopes, Iodine Radioisotopes.
- chemical , immunology : Immunoglobulin M, Receptors, Antigen, B-Cell.
- chemical , metabolism : Antibodies, Anti-Idiotypic, Antibodies, Bispecific, Haptens, Receptors, Antigen, B-Cell.
- metabolism : Lymphoma, B-Cell.
- Cells, Cultured, Endocytosis, Humans, Hydrogen-Ion Concentration.
Abstract
The efficiency of radioimmunotherapy with iodine-labelled antibodies is often limited by intracellular internalisation and catabolism after initial binding to the cellular targets. We have developed a technique called affinity enhancement system (AES) which uses bi-specific antibodies to target radiolabelled bivalent haptens to cells. This targeting method has been applied successfully to tumour imaging in colorectal cancer patients and is now considered for therapy. We have investigated the potential of this technique to target iodine radioisotopes by comparing it to targeting with covalently iodine-labelled antibodies in a rapidly internalising antigenic system, the surface IgM of a B-lymphoma cell line. A 5-fold increase in the intracellular retention time of activity as compared to 125I-labelled F(ab')2 or IgG was observed. The radiolabelled hapten did not undergo any catabolism after internalisation. Resistance to cellular proteases and failure of recognition of the hapten by amino acid transporter systems may be potential explanations for these observations. This should make non-covalent targeting, particularly the AES, a method of choice to target modulating antigens for the therapy of malignant hemopathies.
PubMed: 7591213
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.</title><author><name sortKey="Manetti, C" uniqKey="Manetti C">C Manetti</name><affiliation wicri:level="1"><nlm:affiliation>IMMUNOTECH S.A., Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IMMUNOTECH S.A., Marseille</wicri:regionArea><placeName><region type="région">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Le Doussal, J M" uniqKey="Le Doussal J">J M Le Doussal</name></author><author><name sortKey="Rouvier, E" uniqKey="Rouvier E">E Rouvier</name></author><author><name sortKey="Gruaz Guyon, A" uniqKey="Gruaz Guyon A">A Gruaz-Guyon</name></author><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name></author></titleStmt><publicationStmt><date when="1995">1995</date><idno type="RBID">pubmed:7591213</idno><idno type="pmid">7591213</idno><idno type="wicri:Area/Main/Corpus">004874</idno><idno type="wicri:Area/Main/Curation">004874</idno><idno type="wicri:Area/Main/Exploration">004665</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Anti-Idiotypic (metabolism)</term><term>Antibodies, Bispecific (metabolism)</term><term>Cells, Cultured</term><term>Endocytosis</term><term>Haptens (metabolism)</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Immunoglobulin M (immunology)</term><term>Indium Radioisotopes (diagnostic use)</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Lymphoma, B-Cell (metabolism)</term><term>Receptors, Antigen, B-Cell (immunology)</term><term>Receptors, Antigen, B-Cell (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Immunoglobulin M</term><term>Receptors, Antigen, B-Cell</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Anti-Idiotypic</term><term>Antibodies, Bispecific</term><term>Haptens</term><term>Receptors, Antigen, B-Cell</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphoma, B-Cell</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cells, Cultured</term><term>Endocytosis</term><term>Humans</term><term>Hydrogen-Ion Concentration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficiency of radioimmunotherapy with iodine-labelled antibodies is often limited by intracellular internalisation and catabolism after initial binding to the cellular targets. We have developed a technique called affinity enhancement system (AES) which uses bi-specific antibodies to target radiolabelled bivalent haptens to cells. This targeting method has been applied successfully to tumour imaging in colorectal cancer patients and is now considered for therapy. We have investigated the potential of this technique to target iodine radioisotopes by comparing it to targeting with covalently iodine-labelled antibodies in a rapidly internalising antigenic system, the surface IgM of a B-lymphoma cell line. A 5-fold increase in the intracellular retention time of activity as compared to 125I-labelled F(ab')2 or IgG was observed. The radiolabelled hapten did not undergo any catabolism after internalisation. Resistance to cellular proteases and failure of recognition of the hapten by amino acid transporter systems may be potential explanations for these observations. This should make non-covalent targeting, particularly the AES, a method of choice to target modulating antigens for the therapy of malignant hemopathies.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7591213</PMID><DateCreated><Year>1995</Year><Month>12</Month><Day>04</Day></DateCreated><DateCompleted><Year>1995</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2007</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0020-7136</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Month>Oct</Month><Day>9</Day></PubDate></JournalIssue><Title>International journal of cancer. Journal international du cancer</Title><ISOAbbreviation>Int. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.</ArticleTitle><Pagination><MedlinePgn>250-6</MedlinePgn></Pagination><Abstract><AbstractText>The efficiency of radioimmunotherapy with iodine-labelled antibodies is often limited by intracellular internalisation and catabolism after initial binding to the cellular targets. We have developed a technique called affinity enhancement system (AES) which uses bi-specific antibodies to target radiolabelled bivalent haptens to cells. This targeting method has been applied successfully to tumour imaging in colorectal cancer patients and is now considered for therapy. We have investigated the potential of this technique to target iodine radioisotopes by comparing it to targeting with covalently iodine-labelled antibodies in a rapidly internalising antigenic system, the surface IgM of a B-lymphoma cell line. A 5-fold increase in the intracellular retention time of activity as compared to 125I-labelled F(ab')2 or IgG was observed. The radiolabelled hapten did not undergo any catabolism after internalisation. Resistance to cellular proteases and failure of recognition of the hapten by amino acid transporter systems may be potential explanations for these observations. This should make non-covalent targeting, particularly the AES, a method of choice to target modulating antigens for the therapy of malignant hemopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manetti</LastName><ForeName>C</ForeName><Initials>C</Initials><Affiliation>IMMUNOTECH S.A., Marseille, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Le Doussal</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rouvier</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gruaz-Guyon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Int J Cancer</MedlineTA><NlmUniqueID>0042124</NlmUniqueID><ISSNLinking>0020-7136</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Anti-Idiotypic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Haptens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Antigen, B-Cell</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Haptens</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymphoma, B-Cell</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7591213</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004665 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004665 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:7591213
|texte= Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:7591213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |